IL-2 injections before surgery for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether injections of a medicine called interleukin-2 (IL-2) into the tumor before surgery can improve outcomes for people with triple-negative breast cancer. It may help by boosting the body’s immune response, but it also requires frequent hospital visits and careful safety screening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed by biopsy with triple-negative breast cancer
- Your tumor is small (2 cm or less) and there is no known lymph node spread (T1N0)
- Your treatment plan is to have surgery first (not chemotherapy before surgery), and you may not be able to safely take chemotherapy
- You can give informed consent and are able to come to the hospital for injection and study visits
- You are between 18 and 80 years old, and you are not pregnant or breastfeeding
- Your heart, lungs, and kidney function must be safe for IL-2, and you have not had serious IL-2 side effects before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests a new combination of two immunotherapy drugs (INBRX-106 and pembrolizumab) given before surgery for people with early-stage triple-negative breast cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) before surgery can improve outcomes for people with early-stage triple-negative breast cancer. It aims to shrink the tumor and increase the chance of a complete response.
This trial studies a short course of sintilimab (an immune treatment) added to standard chemotherapy drugs before surgery for triple-negative breast cancer. It may help shrink the tumor and improve outcomes by boosting the immune system while you receive treatment.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This study tests a combination of chemotherapy and immunotherapy given before surgery for triple-negative breast cancer. It aims to shrink the tumor and improve outcomes. The treatment is given intravenously.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.